We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
BTF3 is not prognostic in Glioblastoma Multiforme (TCGA)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: 0.98
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
0.12
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
12%
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
3%
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
507.9
Number of samples
141
Samples
Sample
Description
TPM
TCGA-06-5417-01A
45 years, female, white, stage:'--, alive, 155 days
948.0
TCGA-06-0178-01A
38 years, male, white, stage:'--, dead, 2681 days
898.3
TCGA-14-1823-01A
58 years, female, white, stage:'--, dead, 543 days
778.7
TCGA-32-5222-01A
66 years, male, white, stage:'--, dead, 585 days
755.6
TCGA-02-2483-01A
43 years, male, asian, stage:'--, alive, 466 days
743.6
TCGA-06-2565-01A
59 years, male, asian, stage:'--, dead, 506 days
733.0
TCGA-28-5216-01A
52 years, male, white, stage:'--, alive, 415 days
732.8
TCGA-28-5208-01A
52 years, male, white, stage:'--, dead, 544 days
729.9
TCGA-12-5295-01A
60 years, female, white, stage:'--, dead, 454 days
728.8
TCGA-06-5413-01A
67 years, male, white, stage:'--, alive, 268 days
713.3
TCGA-41-5651-01A
59 years, female, black or african american, stage:'--, dead, 460 days
694.7
TCGA-06-5856-01A
58 years, male, white, stage:'--, dead, 114 days
684.5
TCGA-02-2485-01A
53 years, male, black or african american, stage:'--, alive, 470 days
682.9
TCGA-27-2523-01A
63 years, male, white, stage:'--, dead, 489 days
675.6
TCGA-27-2528-01A
62 years, male, white, stage:'--, dead, 480 days
675.3
TCGA-12-3652-01A
60 years, male, white, stage:'--, dead, 1062 days
672.4
TCGA-06-5408-01A
54 years, female, white, stage:'--, dead, 357 days
664.0
TCGA-14-2554-01A
52 years, female, white, stage:'--, dead, 532 days
638.3
TCGA-14-1829-01A
57 years, male, black or african american, stage:'--, alive, 218 days
635.2
TCGA-06-2563-01A
72 years, female, white, stage:'--, alive, 932 days
631.5
TCGA-27-2524-01A
56 years, male, white, stage:'--, dead, 231 days
630.9
TCGA-12-3650-01A
46 years, male, white, stage:'--, dead, 333 days
629.3
TCGA-14-0817-01A
69 years, female, white, stage:'--, dead, 164 days
628.8
TCGA-19-5960-01A
56 years, male, white, stage:'--, dead, 455 days
623.3
TCGA-02-0055-01A
62 years, female, white, stage:'--, dead, 76 days
621.5
TCGA-06-0174-01A
54 years, male, white, stage:'--, dead, 98 days
621.4
TCGA-06-2559-01A
83 years, male, white, stage:'--, dead, 150 days
618.8
TCGA-14-0787-01A
69 years, male, asian, stage:'--, dead, 68 days
616.9
TCGA-06-5416-01A
23 years, female, white, stage:'--, alive, 204 days
615.8
TCGA-02-2486-01A
64 years, male, white, stage:'--, dead, 618 days
613.9
TCGA-28-5204-01A
72 years, male, white, stage:'--, dead, 454 days
612.9
TCGA-14-1825-01A
70 years, male, white, stage:'--, dead, 232 days
612.2
TCGA-32-2634-01A
82 years, male, white, stage:'--, alive, 693 days
608.5
TCGA-06-0238-01A
46 years, male, white, stage:'--, dead, 405 days
606.1
TCGA-06-2570-01A
21 years, female, white, stage:'--, alive, 958 days
604.5
TCGA-28-2509-01A
77 years, female, white, stage:'--, alive, 145 days
593.1
TCGA-12-5299-01A
56 years, female, white, stage:'--, dead, 98 days
592.7
TCGA-28-5207-01A
71 years, male, white, stage:'--, dead, 343 days
591.2
TCGA-06-2558-01A
75 years, female, white, stage:'--, dead, 380 days
567.8
TCGA-12-0616-01A
36 years, female, white, stage:'--, dead, 448 days
565.3
TCGA-27-2521-01A
34 years, male, white, stage:'--, dead, 510 days
565.1
TCGA-28-5220-01A
67 years, male, white, stage:'--, dead, 388 days
557.2
TCGA-06-2562-01A
81 years, male, white, stage:'--, dead, 382 days
553.8
TCGA-76-4932-01A
50 years, female, white, stage:'--, dead, 1458 days
548.4
TCGA-19-1390-01A
63 years, female, white, stage:'--, dead, 772 days
547.0
TCGA-06-0219-01A
67 years, male, white, stage:'--, dead, 22 days
546.1
TCGA-12-0821-01A
62 years, male, white, stage:'--, dead, 323 days
545.6
TCGA-28-5209-01A
66 years, female, white, stage:'--, alive, 442 days
545.6
TCGA-27-2526-01A
79 years, female, white, stage:'--, dead, 87 days
545.1
TCGA-06-0190-01A
62 years, male, white, stage:'--, dead, 317 days
544.9
TCGA-06-0130-01A
54 years, male, white, stage:'--, dead, 394 days
530.9
TCGA-14-1034-01A
60 years, female, stage:'--, dead, 485 days
529.8
TCGA-15-0742-01A
65 years, male, white, stage:'--, dead, 419 days
526.8
TCGA-06-0878-01A
74 years, male, white, stage:'--, alive, 218 days
526.2
TCGA-06-0210-01A
72 years, female, white, stage:'--, dead, 225 days
525.2
TCGA-06-5412-01A
78 years, female, white, stage:'--, dead, 138 days
524.7
TCGA-06-5411-01A
51 years, male, white, stage:'--, dead, 254 days
520.8
TCGA-06-5414-01A
61 years, male, white, stage:'--, alive, 273 days
519.9
TCGA-76-4925-01A
76 years, male, white, stage:'--, dead, 146 days
519.5
TCGA-32-2632-01A
80 years, male, white, stage:'--, dead, 269 days
517.0
TCGA-06-0686-01A
53 years, male, white, stage:'--, dead, 432 days
510.3
TCGA-19-2629-01A
60 years, male, white, stage:'--, dead, 737 days
509.1
TCGA-32-2615-01A
62 years, male, white, stage:'--, dead, 485 days
506.6
TCGA-12-3653-01A
34 years, female, white, stage:'--, dead, 442 days
506.2
TCGA-28-2514-01A
45 years, male, asian, stage:'--, alive, 160 days
504.8
TCGA-06-0138-01A
43 years, male, white, stage:'--, dead, 737 days
503.0
TCGA-06-0744-01A
66 years, male, white, stage:'--, dead, 1426 days
497.8
TCGA-26-5139-01A
65 years, female, white, stage:'--, alive, 48 days
496.6
TCGA-76-4931-01A
70 years, female, white, stage:'--, dead, 279 days
496.5
TCGA-06-0139-01A
40 years, male, white, stage:'--, dead, 362 days
495.7
TCGA-06-0644-01A
71 years, male, black or african american, stage:'--, dead, 384 days
494.1
TCGA-06-0645-01A
55 years, female, white, stage:'--, dead, 175 days
492.7
TCGA-19-4065-01A
36 years, male, white, stage:'--, alive, 214 days
492.5
TCGA-27-1831-01A
66 years, male, white, stage:'--, dead, 505 days
491.5
TCGA-06-2564-01A
50 years, male, white, stage:'--, alive, 181 days
491.4
TCGA-06-0129-01A
30 years, male, asian, stage:'--, dead, 1024 days
490.7
TCGA-12-0618-01A
49 years, male, white, stage:'--, dead, 395 days
489.8
TCGA-06-0211-01A
47 years, male, white, stage:'--, dead, 360 days
488.0
TCGA-19-2620-01A
70 years, male, white, stage:'--, dead, 148 days
485.9
TCGA-06-5859-01A
63 years, male, white, stage:'--, alive, 139 days
484.3
TCGA-28-5218-01A
63 years, male, white, stage:'--, dead, 157 days
481.9
TCGA-27-1830-01A
57 years, male, white, stage:'--, dead, 154 days
480.1
TCGA-76-4927-01A
58 years, male, white, stage:'--, dead, 535 days
479.5
TCGA-06-0156-01A
57 years, male, white, stage:'--, dead, 178 days
477.2
TCGA-06-5858-01A
45 years, female, white, stage:'--, alive, 187 days
476.7
TCGA-32-2638-01A
67 years, male, white, stage:'--, dead, 766 days
473.0
TCGA-14-0789-01A
54 years, male, white, stage:'--, dead, 342 days
468.1
TCGA-32-1982-01A
76 years, female, white, stage:'--, dead, 142 days
461.8
TCGA-06-0184-01A
63 years, male, white, stage:'--, dead, 2126 days
456.5
TCGA-06-5418-01A
75 years, female, white, stage:'--, dead, 83 days
455.6
TCGA-26-1442-01A
43 years, male, white, stage:'--, alive, 953 days
449.5
TCGA-19-2619-01A
55 years, female, black or african american, stage:'--, alive, 294 days
443.9
TCGA-06-0125-01A
63 years, female, white, stage:'--, dead, 1448 days
443.4
TCGA-06-2557-01A
76 years, male, black or african american, stage:'--, dead, 33 days
442.9
TCGA-06-5410-01A
72 years, female, white, stage:'--, dead, 108 days
439.1
TCGA-15-1444-01A
21 years, male, white, stage:'--, dead, 1537 days
438.3
TCGA-14-0871-01A
74 years, female, white, stage:'--, dead, 880 days
436.0
TCGA-27-1832-01A
59 years, female, white, stage:'--, dead, 300 days
431.0
TCGA-28-5215-01A
62 years, female, white, stage:'--, dead, 335 days
426.1
TCGA-32-2616-01A
48 years, female, white, stage:'--, dead, 224 days
423.2
TCGA-26-5132-01A
74 years, male, white, stage:'--, alive, 286 days
421.0
TCGA-28-1753-01A
53 years, male, white, stage:'--, alive, 37 days
415.2
TCGA-06-0168-01A
59 years, female, white, stage:'--, dead, 598 days
414.0
TCGA-06-2567-01A
65 years, male, white, stage:'--, dead, 133 days
412.8
TCGA-06-0158-01A
73 years, male, white, stage:'--, dead, 329 days
411.9
TCGA-26-5135-01A
72 years, female, white, stage:'--, dead, 270 days
409.6
TCGA-32-1980-01A
72 years, male, white, stage:'--, dead, 36 days
408.0
TCGA-41-3915-01A
48 years, male, white, stage:'--, dead, 360 days
407.6
TCGA-06-2561-01A
53 years, female, white, stage:'--, dead, 537 days
407.2
TCGA-16-0846-01A
85 years, male, white, stage:'--, dead, 119 days
404.4
TCGA-06-0882-01A
30 years, male, white, stage:'--, dead, 632 days
404.3
TCGA-06-0187-01A
69 years, male, white, stage:'--, dead, 828 days
402.6
TCGA-06-0157-01A
63 years, female, white, stage:'--, dead, 97 days
399.6
TCGA-19-2624-01A
51 years, male, white, stage:'--, dead, 5 days
399.2
TCGA-27-1834-01A
56 years, male, white, stage:'--, dead, 1233 days
398.1
TCGA-41-4097-01A
63 years, female, white, stage:'--, dead, 6 days
391.7
TCGA-27-2519-01A
48 years, male, white, stage:'--, dead, 550 days
388.3
TCGA-06-2569-01A
24 years, female, black or african american, stage:'--, alive, 13 days
388.0
TCGA-28-2513-01A
69 years, female, white, stage:'--, alive, 222 days
387.6
TCGA-06-0750-01A
43 years, male, white, stage:'--, dead, 28 days
386.9
TCGA-27-1835-01A
53 years, female, white, stage:'--, dead, 648 days
386.3
TCGA-41-2572-01A
67 years, male, white, stage:'--, dead, 406 days
385.2
TCGA-76-4929-01A
76 years, female, white, stage:'--, dead, 111 days
385.2
TCGA-12-0619-01A
60 years, male, white, stage:'--, dead, 1062 days
382.8
TCGA-27-1837-01A
36 years, male, white, stage:'--, dead, 427 days
378.9
TCGA-06-0749-01A
50 years, male, black or african american, stage:'--, dead, 82 days
378.4
TCGA-06-0747-01A
53 years, male, white, stage:'--, dead, 82 days
376.1
TCGA-06-0646-01A
60 years, male, white, stage:'--, dead, 175 days
372.7
TCGA-41-2571-01A
89 years, male, white, stage:'--, dead, 26 days
371.5
TCGA-32-1970-01A
59 years, male, white, stage:'--, dead, 468 days
371.3
TCGA-19-2625-01A
76 years, female, white, stage:'--, dead, 124 days
367.2
TCGA-02-0047-01A
78 years, male, white, stage:'--, dead, 448 days
357.8
TCGA-08-0386-01A
74 years, male, white, stage:'--, dead, 548 days
353.4
TCGA-06-0132-01A
49 years, male, white, stage:'--, dead, 771 days
347.3
TCGA-06-0141-01A
62 years, male, white, stage:'--, dead, 313 days
332.8
TCGA-06-0745-01A
59 years, male, white, stage:'--, dead, 239 days
326.5
TCGA-06-0743-01A
69 years, male, white, stage:'--, dead, 803 days
321.1
TCGA-26-5133-01A
59 years, male, white, stage:'--, alive, 452 days
296.6
TCGA-32-4213-01A
47 years, female, white, stage:'--, alive, 604 days
296.2
TCGA-06-1804-01A
81 years, female, white, stage:'--, dead, 414 days
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
BTF3 is not prognostic in Glioblastoma Multiforme (validation)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: 0.99
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
0.021
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
0%
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
37%
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
59.1
Number of samples
58
Samples
Sample
Description
TPM
AK156
N, NA, stage:NA, dead, 330 days
124.1
AK133
N, NA, stage:NA, dead, 360 days
117.1
AK002
N, NA, stage:NA, dead, 570 days
113.3
AK195
N, NA, stage:NA, dead, 390 days
98.1
AK205
N, NA, stage:NA, dead, 120 days
93.3
AK123
N, NA, stage:NA, dead, 180 days
84.4
AK183
N, NA, stage:NA, alive, 360 days
82.2
AK041
N, NA, stage:NA, alive, 810 days
77.9
AK099
N, NA, stage:NA, dead, 420 days
74.3
AK142
N, NA, stage:NA, alive, 90 days
72.9
AK035
N, NA, stage:NA, dead, 210 days
72.5
AK165
N, NA, stage:NA, alive, 360 days
70.4
AK072
N, NA, stage:NA, dead, 150 days
69.7
AK236
N, NA, stage:NA, dead, 360 days
69.7
AK218
N, NA, stage:NA, dead, 180 days
69.0
AK051
N, NA, stage:NA, dead, 360 days
68.8
AK079
N, NA, stage:NA, dead, 210 days
67.5
AK117
N, NA, stage:NA, dead, 210 days
67.2
AK081
N, NA, stage:NA, dead, 180 days
66.8
AK134
N, NA, stage:NA, dead, 360 days
64.0
AK085
N, NA, stage:NA, alive, 660 days
62.4
AK030
N, NA, stage:NA, dead, 120 days
58.9
AK153
N, NA, stage:NA, dead, 240 days
57.2
AK124
N, NA, stage:NA, alive, 1920 days
57.0
AK149
N, NA, stage:NA, dead, 420 days
56.7
AK066
N, NA, stage:NA, alive, 960 days
55.8
AK226
N, NA, stage:NA, dead, 360 days
55.3
AK158
N, NA, stage:NA, dead, 360 days
54.5
AK088
N, NA, stage:NA, dead, 360 days
54.4
AK089
N, NA, stage:NA, dead, 330 days
53.6
AK199
N, NA, stage:NA, alive, 1860 days
53.0
AK043
N, NA, stage:NA, alive, 660 days
51.9
AK173
N, NA, stage:NA, dead, 180 days
51.0
AK103
N, NA, stage:NA, alive, 1320 days
50.1
AK139
N, NA, stage:NA, dead, 270 days
48.2
AK005
N, NA, stage:NA, dead, 240 days
48.2
AK049
N, NA, stage:NA, dead, 180 days
47.4
AK068
N, NA, stage:NA, alive, 360 days
47.4
AK167
N, NA, stage:NA, dead, 180 days
47.3
AK102
N, NA, stage:NA, alive, 1740 days
45.8
AK213
N, NA, stage:NA, alive, 2010 days
45.7
AK227
N, NA, stage:NA, alive, 300 days
45.5
AK188
N, NA, stage:NA, alive, 420 days
45.3
AK098
N, NA, stage:NA, dead, 660 days
44.2
AK185
N, NA, stage:NA, alive, 330 days
44.1
AK015
N, NA, stage:NA, alive, 720 days
43.9
AK231
N, NA, stage:NA, dead, 240 days
43.5
AK074
N, NA, stage:NA, alive, 300 days
43.4
AK178
N, NA, stage:NA, dead, 240 days
43.0
AK216
N, NA, stage:NA, dead, 360 days
42.4
AK091
N, NA, stage:NA, dead, 210 days
42.1
AK076
N, NA, stage:NA, alive, 660 days
41.8
AK006
N, NA, stage:NA, dead, 360 days
40.9
AK071
N, NA, stage:NA, dead, 540 days
40.0
AK003
N, NA, stage:NA, dead, 600 days
38.5
AK055
N, NA, stage:NA, dead, 240 days
37.1
AK100
N, NA, stage:NA, alive, 960 days
36.0
AK053
N, NA, stage:NA, dead, 300 days
34.6
Show allShow less
GLIOBLASTOMA MULTIFORME - Protein relative expression (CPTAC)
Number of samples
110
Samples
Sample ID
Sample type
nRPX
CPT0168080003
Tumor
0.9
CPT0217710008
Tumor
0.8
CPT0228220003
Tumor
0.7
CPT0078580003
Tumor
0.6
CPT0093510003
Tumor
0.6
CPT0161730003
Tumor
0.6
CPT0224390004
Tumor
0.5
CPT0168480003
Tumor
0.4
CPT0167860004
Tumor
0.4
CPT0218830004
Tumor
0.4
CPT0168380003
Tumor
0.4
CPT0205890003
Tumor
0.3
CPT0217060003
Tumor
0.3
CPT0093450003
Tumor
0.3
CPT0093590003
Tumor
0.3
CPT0189570004
Tumor
0.3
CPT0224600003
Tumor
0.3
CPT0221180003
Tumor
0.3
CPT0218330004
Tumor
0.3
CPT0205670004
Tumor
0.3
CPT0168830003
Tumor
0.3
CPT0217100003
Tumor
0.3
CPT0217430008
Tumor
0.3
CPT0205780003
Tumor
0.3
CPT0207030003
Tumor
0.3
CPT0087680003
Tumor
0.3
CPT0218960004
Tumor
0.2
CPT0127480003
Tumor
0.2
CPT0206560003
Tumor
0.2
CPT0168590003
Tumor
0.2
CPT0206330003
Tumor
0.2
CPT0123530003
Tumor
0.2
CPT0182580003
Tumor
0.2
CPT0216920008
Tumor
0.2
CPT0206780003
Tumor
0.2
CPT0206670004
Tumor
0.2
CPT0225760003
Tumor
0.2
CPT0167750004
Tumor
0.2
CPT0089150003
Tumor
0.1
CPT0206110003
Tumor
0.1
CPT0168720003
Tumor
0.1
CPT0064650003
Tumor
0.1
CPT0208980003
Tumor
0.1
CPT0127420003
Tumor
0.1
CPT0218690004
Tumor
0.1
CPT0079790003
Tumor
0.1
CPT0190360004
Tumor
0.1
CPT0207090003
Tumor
0.1
CPT0225730003
Tumor
0.1
CPT0217880003
Tumor
0.1
CPT0206230003
Tumor
0.1
CPT0190240004
Tumor
0.1
CPT0206000004
Tumor
0.1
CPT0205450004
Tumor
0.0
CPT0093550003
Tumor
0.0
CPT0189750004
Tumor
0.0
CPT0093360003
Tumor
0.0
CPT0218670003
Tumor
0.0
CPT0167970003
Tumor
0.0
CPT0167530003
Tumor
0.0
CPT0064890003
Tumor
0.0
CPT0182500003
Tumor
0.0
CPT0125220003
Tumor
0.0
CPT0171580008
Tumor
0.0
CPT0224540004
Tumor
0.0
CPT0217190003
Tumor
0.0
CPT0209440003
Tumor
0.0
CPT0168270003
Tumor
0.0
CPT0199770003
Tumor
0.0
CPT0167640003
Tumor
0.0
CPT0175060003
Tumor
0.0
CPT0125570003
Tumor
0.0
CPT0092440003
Tumor
0.0
CPT0104330003
Tumor
0.0
CPT0186100003
Tumor
-0.1
CPT0162020003
Tumor
-0.1
CPT0162140003
Tumor
-0.1
CPT0204420003
Normal
-0.1
CPT0182550003
Tumor
-0.1
CPT0087730003
Tumor
-0.1
CPT0002410011
Tumor
-0.1
CPT0189460003
Tumor
-0.1
CPT0125510003
Tumor
-0.1
CPT0201710003
Tumor
-0.1
CPT0206880003
Tumor
-0.1
CPT0204380003
Normal
-0.1
CPT0189650004
Tumor
-0.2
CPT0189850004
Tumor
-0.2
CPT0087570003
Tumor
-0.2
CPT0204400003
Normal
-0.2
CPT0204340003
Normal
-0.2
CPT0204330003
Normal
-0.2
CPT0071100003
Tumor
-0.2
CPT0206450003
Tumor
-0.2
CPT0205570003
Tumor
-0.2
CPT0196850003
Tumor
-0.3
CPT0204370003
Normal
-0.3
CPT0219080004
Tumor
-0.3
CPT0218890004
Tumor
-0.3
CPT0218770003
Tumor
-0.3
CPT0087950003
Tumor
-0.3
CPT0204360003
Normal
-0.3
CPT0204390003
Normal
-0.3
CPT0104220003
Tumor
-0.4
CPT0204350003
Normal
-0.4
CPT0204410003
Normal
-0.4
CPT0162100003
Tumor
-0.5
CPT0189250003
Tumor
-0.5
CPT0224330003
Tumor
-0.6
CPT0217000004
Tumor
-0.7
Show allShow less
GLIOMA - Protein expressioni
A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.
Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.
Antibody stainingi
Antibody staining in the annotated cell types in the current human tissue is reported as not detected, low, medium, or high, based on conventional immunohistochemistry profiling in selected tissues. This score is based on the combination of the staining intensity and fraction of stained cells.
Each image is clickable and will lead to virtual microscopy that enables deeper exploration of all samples and also displays staining intensity scores, fraction scores and subcellular localization as well as patient and tissue information for each sample.